TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 8B 16B 24B FY07: 9.4B FY08: 11.1B FY09: 16.1B FY10: 16.1B FY11: 18.3B FY12: 20.3B FY13: 20.3B FY14: 20.3B FY15: 19.7B FY16: 21.9B FY16: 21.9B FY17: 21.9B FY18: 18.3B FY19: 16.9B FY20: 16.7B FY21: 15.9B FY22: 14.9B FY23: 15.8B FY24: 16.5B FY25: 17.3B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 5B 10B 15B FY07: 4.9B FY08: 6B FY09: 7.4B FY10: 9.1B FY11: 9.5B FY12: 10.7B FY13: 10.7B FY14: 11.1B FY15: 11.4B FY16: 11.9B FY16: 11.7B FY17: 10.6B FY18: 8.3B FY19: 7.5B FY20: 7.7B FY21: 7.6B FY22: 7B FY23: 7.6B FY24: 8.1B FY25: 8.9B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-18B -12B -6B 0 6B 12B 18B FY07: 2.4B FY08: 1.1B FY09: 2.4B FY10: 3.9B FY11: 3.1B FY12: 2.2B FY13: 1.6B FY14: 4B FY15: 3.4B FY16: 2.2B FY16: 2.2B FY17: -17.5B FY18: -1.6B FY19: -443M FY20: -3.6B FY21: 1.7B FY22: -2.2B FY23: 433M FY24: -303M FY25: 2.2B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-18B -12B -6B 0 6B 12B 18B FY07: 1.9B FY08: 609M FY09: 2B FY10: 3.3B FY11: 2.8B FY12: 2B FY13: 1.3B FY14: 3.1B FY15: 1.6B FY16: 329M FY16: 329M FY17: -16.3B FY18: -2.1B FY19: -999M FY20: -4B FY21: 417M FY22: -2.4B FY23: -559M FY24: -1.6B FY25: 1.4B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 4B 8B 12B FY07: 4.5B FY08: 5.1B FY09: 6.5B FY10: 7.1B FY11: 8.8B FY12: 9.7B FY13: 9.6B FY14: 9.2B FY15: 8.3B FY16: 10B FY16: 10.2B FY17: 11.2B FY18: 10B FY19: 9.4B FY20: 8.9B FY21: 8.3B FY22: 8B FY23: 8.2B FY24: 8.5B FY25: 8.3B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

0 2B 4B 6B FY07: 1.8B FY08: 3.2B FY09: 3.4B FY10: 4.1B FY11: 4.1B FY12: 4.6B FY13: 3.2B FY14: 5.1B FY15: 5.5B FY16: 5.2B FY16: 3.9B FY17: 2.2B FY18: 2.4B FY19: 748M FY20: 1.2B FY21: 798M FY22: 1.6B FY23: 1.4B FY24: 1.2B FY25: 1.6B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

0 2B 4B 6B FY07: 1.3B FY08: 2.5B FY09: 2.7B FY10: 3.4B FY11: 3.1B FY12: 3.5B FY13: 2.2B FY14: 4.2B FY15: 4.8B FY16: 4.3B FY16: 3B FY17: 1.4B FY18: 1.8B FY19: 223M FY20: 638M FY21: 236M FY22: 1B FY23: 842M FY24: 749M FY25: 1.1B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 400M 800M 1.2B FY07: 830M FY08: 820M FY09: 896M FY10: 921M FY11: 893M FY12: 873M FY13: 850M FY14: 858M FY15: 864M FY16: 961M FY16: 961 FY17: 1B FY18: 1B FY19: 1.1B FY20: 1.1B FY21: 1.1B FY22: 1.1B FY23: 1.1B FY24: 1.1B FY25: 1.2B FY08 FY10 FY12 FY14 FY16 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '09: 2.23 Q1 '10: 2.51 Q2 '10: 2.81 Q3 '10: 3.24 Q4 '10: 3.67 Q1 '11: 3.72 Q2 '11: 3.48 Q3 '11: 3.36 Q4 '11: 3.09 Q1 '12: 3.22 Q2 '12: 3.57 Q3 '12: 2.45 Q4 '12: 2.24 Q1 '13: 2.01 Q2 '13: 0.49 Q3 '13: 1.42 Q4 '13: 1.50 Q1 '14: 1.63 Q2 '14: 3.03 Q3 '14: 3.21 Q4 '14: 3.56 Q1 '15: 3.21 Q2 '15: 2.97 Q3 '15: 2.07 Q4 '15: 1.83 Q1 '16: 1.93 Q4 '16: 0.07 Q1 '17: 0.10 Q2 '17: -6.04 Q3 '17: -5.87 Q4 '17: -16.26 Q1 '18: -15.80 Q2 '18: -10.10 Q3 '18: -10.89 Q4 '18: -2.33 Q1 '19: -3.46 Q2 '19: -3.85 Q3 '19: -3.87 Q4 '19: -0.92 Q1 '20: -0.76 Q2 '20: 0.00 Q3 '20: -3.68 Q4 '20: -3.64 Q1 '21: -3.63 Q2 '21: -3.57 Q3 '21: 0.66 Q4 '22: -2.19 Q1 '23: -1.53 Q2 '23: -2.10 Q3 '23: -2.09 Q4 '23: -0.50 Q1 '24: -0.42 Q2 '24: -0.39 Q3 '24: -0.84 Q4 '24: -1.45 Q1 '25: -1.15 Q2 '25: -0.16 Q3 '25: 0.60 Q4 '25: 1.20 Q1 '26: 1.33 Q2 '26: 0.60 Q4 '10 Q4 '12 Q4 '14 Q2 '17 Q2 '19 Q2 '21 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.